NIH Research Festival
The National Cancer Institute’s Office of Cancer Genomics (OCG) aims to advance the molecular understanding of cancers with the goal to improve patient outcomes. OCG supports structural, functional, and computational genomic programs to accelerate the translation of findings into the clinic and advance precision oncology. The Cancer Target Discovery and Development (CTD^2) Network advances cancer research by bridging the knowledge gap between cancer genetics and biology. The CTD^2 Network aims to understand the tumor heterogeneity and drug resistance for the development of efficient strategies to identify optimal combinations of small-molecules or immunotherapy with small molecules. The Network emphasizes collaborations between Centers which have complementary and distinctive expertise in various systems and functional biology approaches. The Human Cancer Models Initiative (HCMI) is an international consortium which will develop next generation patient-derived cancer models representative of the biology and complexity of human tumors. Models will be molecularly characterized and clinically annotated, and models and data will be available as a community resource. The Cancer Genome Characterization Initiative (CGCI) and Therapeutically Applicable Research to Generate Effective Treatments (TARGET) use comprehensive genomic, transcriptomic, and epigenomic approaches to analyze tumor and patient-matched normal tissue samples with the goal of identifying therapeutic targets and biomarkers. CGCI characterizes both adult and pediatric cancers, including those prevalent in HIV-positive individuals, while TARGET predominantly characterizes high-risk cancers affecting children and young adults. Data, analytical tools, and resources generated by OCG programs are made available through the OCG website (https://ocg.cancer.gov/) to the research community.
Scientific Focus Area: Cancer Biology
This page was last updated on Friday, March 26, 2021